Price Alert

Skye Bioscience Inc. (SKYE)

NASDAQ: SKYE · Real-Time Price · USD

4.75

0.26 (5.79%)

At close: Oct 03, 2025, 3:59 PM

4.80

1.01%

After-hours: Oct 03, 2025, 07:55 PM EDT

5.79% (1D)

Bid	4.7
Market Cap	147.19M
Revenue (ttm)	n/a
Net Income (ttm)	-42.37M
EPS (ttm)	-1.15
PE Ratio (ttm)	-4.13
Forward PE	-3.25
Analyst	Buy
Dividends	n/a

Ask	5
Volume	658,808
Avg. Volume (20D)	437,454.8
Open	4.56
Previous Close	4.49
Day's Range	4.46 - 4.99
52-Week Range	1.14 - 5.96
Beta	2.35
Ex-Dividend Date	n/a

About SKYE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SKYE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+32.87%

Skye Bioscience shares are trading higher after th... Unlock content with Pro Subscription

4 months ago

+14.97%

Skye Bioscience shares are trading higher after the company announced a collaboration with Arecor to improve dosing and patient compliance.

News

3 days ago · seekingalpha.com

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Skye Bioscience is rated Buy, driven by nimacimab's strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE's nimacimab targets the expanding anti-obesity market, showing poten...

3 weeks ago · seekingalpha.com

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience, Inc. (NASDAQ:SKYE ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Punit Dhillon - President, CEO, Secretary & Director Co...

1 month ago · benzinga.com

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

On Thursday, Skye Bioscience Inc. SKYE reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

1 month ago · seekingalpha.com

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience, Inc. (NASDAQ:SKYE ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kaitlyn Melanie Arsenault - Chief Financial Officer Puneet S. Arora - Chief Medical...

2 months ago · seekingalpha.com

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is it...